SequelSEC

WINDTREE THERAPEUTICS INC /DE/ WINT

Biological Products, (No Diagnostic Substances) · CIK 0000946486 · Fiscal year ends 1231

Revenue
$198.00K
Fiscal year ended 2019-12-31
Operating income
-$24.89M
Fiscal year ended 2019-12-31
Free cash flow
-$24.85M
Fiscal year ended 2019-12-31

WINDTREE THERAPEUTICS INC /DE/ (WINT) reported revenue of $198.00K and net income of -$27.48M for the fiscal year ended 2019-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from WINDTREE THERAPEUTICS INC /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

WINDTREE THERAPEUTICS INC /DE/ income by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Revenue$198.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$24.89M
Net income-$27.48M
Research & development$12.69M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$12.40M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

WINDTREE THERAPEUTICS INC /DE/ balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Cash & equivalents$22.58M
Total assets$118.98M
Current assets$23.86M
Total liabilities$44.04M
Current liabilities$7.82M
Total equity incl. NCI$74.94M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
Goodwill$15.68M
Long-term debtUnavailable
Accounts payable$1.71M

Cash flow

WINDTREE THERAPEUTICS INC /DE/ cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Operating cash flow-$24.66M
Capital expenditures$191.00K
Investing cash flow$13.80M
Financing cash flow$21.77M
Net change in cash$11.37M
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

WINDTREE THERAPEUTICS INC /DE/ derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2019-12-31
Free cash flow-$24.85M
Gross marginUnavailable
Operating margin-12572.2%
FCF margin-12552.5%
SBC / revenueUnavailable
Current ratio3.05x
Revenue YoY growth-88.9%
Net margin-13876.3%
R&D / revenue6407.6%
CapEx / revenue96.5%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open WINT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-K · Filed 2025-04-15View SEC filing
10-Q · Filed 2024-11-26View SEC filing
10-Q · Filed 2024-08-19View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.